Patient safety guidance should include: Education about expected appetite changes and strategies for maintaining adequate nutrition Monitoring for excessive weight loss or signs of malnutrition Assessment of mental health at follow-up visits Clear instructions to report severe or persistent nausea, vomiting, or neuropsychiatric symptoms Awareness that cognitive effects remain investigational and should not influence prescribing decisions Reporting severe persistent abdominal pain (pancreatitis), right upper quadrant pain/jaundice (gallbladder disease), severe abdominal distension with inability to pass gas or stool (possible ileus), persistent vomiting or signs of dehydration, and new/worsening vision changes (retinopathy) Understanding increased hypoglycemia risk when combined with insulin or sulfonylureas GLP-1 receptor agonists are contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and should be used with caution in patients with severe gastrointestinal disease, including gastroparesis
The cell-seeded scaffold was placed in a well of a 12 well polymer-bottom plate and submerged in phenol-free media
Appl Microbiol Biot
The opportunity for 2026 isnt another hot take on Ozempic
Nausea is the most common side effect, which generally subsides as a persons body adjusts to the medication
You may have to keep increasing the dosage before you see an effect. It all goes back to managing your expectations and knowing it may take time to figure out the best dose for you
